Results 211 to 220 of about 1,466,333 (379)

Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin   +6 more
wiley   +1 more source

A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells [PDF]

open access: hybrid, 2004
Joerg Bruenke   +12 more
openalex   +1 more source

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission).
Thomas Lund   +12 more
wiley   +1 more source

A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression

open access: yesScientific Reports
The bispecific antibody IMV-M was designed to selectively bind and cluster death receptor 5 (DR5) upon engaging the tumor antigen MUC16 through a novel mechanism—clustering multiple IMV-M molecules on a single MUC16 molecule.
Victor S. Goldmacher   +3 more
doaj   +1 more source

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

open access: yesJournal of Biological Chemistry, 2021
J. Neijssen   +10 more
semanticscholar   +1 more source

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application

open access: yesThe FEBS Journal, EarlyView.
Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie   +3 more
wiley   +1 more source

Blood group O expression in normal tissues and tumors

open access: yesThe FEBS Journal, EarlyView.
The H antigen (O blood group), the precursor to A and B blood groups, is expressed on human erythrocytes. Two novel monoclonal antibodies generated using sea lamprey immunization, Tn4‐31L and OmcFL3‐02, specifically detect the H antigen on glycan microarrays, glycoproteins, and human cells.
Ea Kristine Clarisse Tulin   +11 more
wiley   +1 more source

130. Targeting of Adenovirus Vectors to Mesothelin Via a Bispecific Antibody Reveals Enhanced Gene Transfer to Human Pancreatic Cancer Cells [PDF]

open access: hybrid, 2004
MA van Geer   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy